Jane Street Group LLC boosted its holdings in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 54.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 97,470 shares of the company's stock after acquiring an additional 34,473 shares during the period. Jane Street Group LLC owned 0.06% of HUTCHMED worth $1,405,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of HCM. Barclays PLC raised its holdings in shares of HUTCHMED by 1,483.6% during the 4th quarter. Barclays PLC now owns 2,407 shares of the company's stock worth $35,000 after acquiring an additional 2,255 shares during the period. Blue Trust Inc. increased its position in HUTCHMED by 99.9% during the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company's stock worth $102,000 after purchasing an additional 3,532 shares during the last quarter. Summit Trail Advisors LLC raised its stake in HUTCHMED by 14.4% during the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock worth $189,000 after purchasing an additional 1,647 shares during the period. OLD Mission Capital LLC acquired a new position in HUTCHMED in the 4th quarter valued at about $230,000. Finally, Marshall Wace LLP acquired a new position in HUTCHMED in the 4th quarter valued at about $261,000. Hedge funds and other institutional investors own 8.82% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on HCM shares. Wall Street Zen downgraded shares of HUTCHMED from a "strong-buy" rating to a "buy" rating in a report on Thursday. HSBC lowered HUTCHMED from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th.
Read Our Latest Research Report on HCM
HUTCHMED Trading Up 1.0%
Shares of NASDAQ:HCM traded up $0.13 during midday trading on Friday, reaching $13.40. 42,598 shares of the company's stock were exchanged, compared to its average volume of 101,429. HUTCHMED has a fifty-two week low of $11.51 and a fifty-two week high of $21.50. The firm's 50 day simple moving average is $14.27 and its two-hundred day simple moving average is $14.98. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07.
HUTCHMED Profile
(
Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Featured Articles
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
